A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions (NCT04538664)
A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Patients With EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to compare the efficacy, as demonstrated by progression-free survival (PFS), in participants treated with amivantamab in combination with chemotherapy, versus chemotherapy alone in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) characterized by EGFR Exon 20ins mutations.
Who can join: Review the eligibility criteria below.
Location: City of Hope 2 — Duarte, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (232 Sites)
Showing the first 25 of 232 sites.
- City of Hope 2 — Duarte, California
- University of California Irvine — Orange, California
- UCLA — Santa Monica, California
- Georgetown University Hospital — Washington D.C., District of Columbia
- H. Lee Moffitt Cancer & Research Institute — Tampa, Florida
- University Cancer And Blood Center LLC — Athens, Georgia
- Henry Ford Hospital — Detroit, Michigan
- Washington University Medical Center — St Louis, Missouri
- Regional Cancer Care Associates LLC — East Brunswick, New Jersey
- Langone Health at NYC University, NYU School of Medicine — New York, New York
- Columbia University Medical Center — New York, New York
- Providence Portland Medical Center — Portland, Oregon
- Sanford Health — Sioux Falls, South Dakota
- Texas Oncology Pa — Tyler, Texas
- Utah Cancer Specialists — Salt Lake City, Utah
- Virginia Cancer Specialists — Fairfax, Virginia
- Blue Ridge Cancer Care — Salem, Virginia
- Chris O'Brien Lifehouse — Camperdown,
- St George Hospital — Kogarah,
- Cabrini Medical Centre — Malvern,
- Sir Charles Gairdner Hospital — Nedlands,
- UZ Leuven — Leuven,
- Algemeen Ziekenhuis Delta — Roeselare,
- CHU UCL Namur - Site Godinne — Yvoir,
- Fundacao Pio XII — Barretos,
📞 Contact the Study Coordinator
Phone: (800) 826-4673
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Carcinoma, Non-Small-Cell Lung
- MYLUNG Consortium Study Protocol 2 — Daphne, Alabama
- A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) — Des Moines, Iowa
- THIO Sequenced With Cemiplimab in Advanced NSCLC — Birmingham, Alabama
- Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study — La Jolla, California
- A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) — Los Angeles, California
Explore by condition: All Carcinoma, Non-Small-Cell Lung clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.